预约演示
更新于：2025-08-05
Olanzapine
奥氮平
更新于：2025-08-05
概要
基本信息
简介Zyprexa® 或奥氮平（一种抗精神病药物）广泛用于治疗精神分裂症、双相1型障碍和伴随这些病症的激越。该药物由礼来研发的一种D1受体抑制剂，可有效调节大脑内多巴胺和血清素的水平。自从1996 年获得欧盟初步批准后，奥氮平已成为治疗各种精神障碍的首选药物。它在治疗此类疾病方面的功效已得到充分证明，使其成为精神疾病患者不可或缺的药物。 该药物在现代医学中发挥着重要的作用，因为它具有调节脑化学的能力，从而为与精神分裂症和双相情感障碍相关的经常失能的症状提供急需的缓解。 |
药物类型 小分子化药 |
别名 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine、Olanzapin、olanzapine LAI + [40] |
作用方式 拮抗剂 |
作用机制 5-HT2A receptor拮抗剂(5-羟色胺2A受体拮抗剂)、5-HT2C receptor拮抗剂(5-羟色胺2C受体拮抗剂)、5-HT3 receptor拮抗剂(5-羟色胺受体3拮抗剂) |
在研适应症 |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C17H20N4S |
InChIKeyKVWDHTXUZHCGIO-UHFFFAOYSA-N |
CAS号132539-06-1 |
关联
554
项与 奥氮平 相关的临床试验NCT06995508
Managing Anorexia During Chemoradiation With Olanzapine (MACRO)
NCT07035821
Olanzapine for the Treatment of Breakthrough Chemotherapy-Induced Vomiting in Children: An Open-label, Randomized Phase 3 Trial
CTR20251993
奥氮平片（5 mg）在中国健康研究参与者中的单次给药、随机、开放、两序列、两周期、双交叉、空腹及餐后状态下的生物等效性研究
100 项与 奥氮平 相关的临床结果
登录后查看更多信息
100 项与 奥氮平 相关的转化医学
登录后查看更多信息
100 项与 奥氮平 相关的专利（医药）
登录后查看更多信息
13,493
项与 奥氮平 相关的文献（医药）2025-12-31JOURNAL OF MEDICAL ECONOMICS
Healthcare resource utilization patterns among patients with Parkinson’s disease psychosis and dementia: analysis of US Medicare beneficiaries treated with pimavanserin versus other-atypical antipsychotics or versus quetiapine
Article
作者: Chrones, Lambros ; Gopal, Daksha ; Doshi, Dilesh ; Rajagopalan, Krithika ; Rashid, Nazia
BACKGROUND:
Pimavanserin (PIM) is the only FDA approved atypical antipsychotic treatment (AAP) for hallucinations and delusions associated with Parkinson's disease psychosis (PDP) among patients with or without coexisting dementia; however, Other-AAPs (i.e. quetiapine (QUE), risperidone, olanzapine, aripiprazole) are commonly prescribed off-label. Healthcare resource utilization (HCRU) patterns among patients with PDP and coexisting dementia (PDP+D) who newly initiate PIM versus (vs.) Other-AAPs (i.e. other AAP-mix) or QUE in real-world settings is limited.
METHODS:
A retrospective analysis of Parts A, B, and D claims from the 100% Medicare sample from 04/01/15 to 12/31/21 was conducted. AAP-naïve patients with PDP+D who initiated ≥12-month continuous monotherapy with PIM vs. Other-AAPs or vs. QUE during 04/01/16-12/31/20 were propensity score matched 1:1 on thirty-one variables (age, sex, race, region and 27 Elixhauser comorbidity characteristics). Adjusted log binomial regressions compared all-cause HCRU [(e.g. inpatient hospitalizations and by hospitalization-type [short-term stays (ST-stays), long-term stays (LT-stays), skilled nursing facility stays (SNF-stays)], and emergency room (ER) visits] risk between cohorts.
RESULTS:
Of the 5,932 patients with PDP+D, matched cohorts (n = 1,294 in each) on continuous- monotherapy of PIM vs. Other-AAPs or QUE had similar demographics and comorbidities. Adjusted regression results showed those who initiated PIM vs. Other-AAPs had significantly lower relative risk (RR) of ≥1 all-cause inpatient hospitalizations (RR = 0.88, 95% CI: 0.80-0.97), ST-stays (RR = 0.86, 95% CI: 0.77-0.95), SNF-stays (RR = 0.79, 95% CI: 0.68-0.92), and ER visits (RR = 0.89, 95% CI: 0.84-0.94). PIM vs. QUE also experienced significantly lower RR for ≥1 all-cause IP hospitalizations (RR = 0.88, 95% CI: 0.80-0.96), ST-stays (RR = 0.85, 95% CI: 0.77-0.95), SNF-stays (RR = 0.81, 95% CI: 0.70-0.94), and ER visits (RR = 0.88, 95% CI: 0.83-0.94).
CONCLUSIONS:
Patients initiating PIM-monotherapy for PDP+D experienced 12% lower all-cause inpatient hospitalizations vs. Other-AAPs or QUE. These results are consistent with prior real-world research in PDP with or without dementia.
2025-10-01JOURNAL OF AFFECTIVE DISORDERS
Investigating the efficacy of levetiracetam as an adjunct to olanzapine for acute manic episodes of bipolar disorder: A double-blind placebo-controlled randomized clinical trial
Article
作者: Nourollahi, Maryam ; Moshfeghinia, Reza ; Jahromi, Leila Razeghian ; Bordbar, Sanaz ; Mirzazadeh, Hasan ; Assadian, Kasra
BACKGROUND:
Bipolar disorder (BD) involves severe mood swings, particularly manic episodes. While antipsychotics like olanzapine are common treatments, adjunct therapies are necessary to improve effectiveness and reduce side effects. This study investigates the safety and efficacy of levetiracetam, an anticonvulsant, as an adjunct treatment for acute mania in BD patients.
METHODS:
This double-blind, placebo-controlled study involved 65 patients diagnosed with bipolar I disorder (BD-I) who were experiencing acute mania. Participants were randomly assigned to receive either levetiracetam combined with olanzapine (n = 32) or a placebo with olanzapine (n = 33) over a period of 16 weeks. The primary outcomes measured included variations in Young Mania Rating Scale (YMRS) scores, Beck Scale for Suicidal Ideation (BSSI) scores, and the occurrence of adverse events. The data analysis was conducted using SPSS-23.
RESULTS:
There were no differences in the baseline characteristics between the case and control groups. The levetiracetam group showed a significantly greater reduction in YMRS scores compared to the placebo group, with mean scores of 2.03 (3.38) versus 16.63 (8.95) at week 16 (P < 0.001). Improvements were noted in subcategories such as mood elevation, motor activity, and sleep disturbances (P < 0.001). BSSI scores decreased in both groups (P < 0.001), but there was no significant difference between the groups (P = 0.07). Adverse events were minimal; however, lethargy occurred more frequently in the levetiracetam group (23.3 % compared to 3.3 %, P = 0.05).
CONCLUSIONS:
Levetiracetam combined with olanzapine may benefit BD patients unresponsive to olanzapine alone. Further research is required to evaluate long-term effects and confirm these findings.
2025-09-01PCN reports : psychiatry and clinical neurosciences
A case of depression with psychotic features associated with hemoglobin Manukau mutation
Article
作者: Zhang, Zhonghao ; Greenberg, Alana ; Thomas, Naveen ; Rose, Linda ; Das, Soumitra ; Jayasooriya, Thilini
Abstract:
Background:
It is pertinent to investigate organic possibilities in acute presentation of mental illness. Iron‐deficiency anemia has long been established to cause symptoms of major depressive disorder. The association between depression and hemolytic anemia and hemochromatosis is less understood.
Case Presentation:
A rare type of hemolytic anemia caused by hemoglobin (Hb) Manukau is reported in a 30‐year‐old female presenting with 3 weeks of severe depression, paranoia, auditory hallucinations, and suicidal ideation. The client was admitted to a psychiatric unit and received treatment with sertraline and olanzapine. Post‐discharge follow up is with a community mental health team. The psychiatric history includes recurrent episodes of major depression with psychotic features, with the first occurring after a stillbirth at age 18 years. The treatment history includes electroconvulsive therapy, sertraline, and olanzapine. The medical complications of the Hb Manukau are chronic hemolytic anemia, liver disease, and hemochromatosis, requiring frequent blood transfusions and iron chelation therapy.
Conclusion:
This rare hemoglobinopathy may contribute to the pathogenesis of recurrent depression with psychotic features, potentially through iron deposition in the brain or by other mechanisms yet to be defined.
100 项与 奥氮平 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 化疗引起的恶心和呕吐 | 日本 | 2017-12-25 | |
| 化疗引起的恶心和呕吐 | 日本 | 2017-12-25 | |
| 躁动 | 美国 | 2009-03-19 | |
| 抑郁症 | 美国 | 2009-03-19 | |
| 难治性抑郁症 | 美国 | 2009-03-19 | |
| 双相情感障碍及相关疾病 | 中国 | 2006-01-01 | |
| 躁郁症1型 | 美国 | 1996-09-30 | |
| 躁郁症 | 欧盟 | 1996-09-27 | |
| 躁郁症 | 冰岛 | 1996-09-27 | |
| 躁郁症 | 列支敦士登 | 1996-09-27 | |
| 躁郁症 | 挪威 | 1996-09-27 | |
| 躁狂 | 欧盟 | 1996-09-27 | |
| 躁狂 | 冰岛 | 1996-09-27 | |
| 躁狂 | 列支敦士登 | 1996-09-27 | |
| 躁狂 | 挪威 | 1996-09-27 | |
| 精神分裂症 | 欧盟 | 1996-09-27 | |
| 精神分裂症 | 冰岛 | 1996-09-27 | |
| 精神分裂症 | 列支敦士登 | 1996-09-27 | |
| 精神分裂症 | 挪威 | 1996-09-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 实体瘤 | 临床3期 | 中国 | 2020-10-01 | |
| 呕吐 | 临床3期 | 中国 | 2020-10-01 | |
| 病理性赌博症 | 临床3期 | 美国 | 2007-02-01 | |
| 体重增加 | 临床3期 | 美国 | 2006-11-01 | |
| 体重增加 | 临床3期 | 巴西 | 2006-11-01 | |
| 体重增加 | 临床3期 | 以色列 | 2006-11-01 | |
| 体重增加 | 临床3期 | 墨西哥 | 2006-11-01 | |
| 体重增加 | 临床3期 | 波多黎各 | 2006-11-01 | |
| 体重增加 | 临床3期 | 俄罗斯 | 2006-11-01 | |
| 边缘性人格障碍 | 临床3期 | 美国 | 2004-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 480 | olanzapine 5mg | 蓋齋壓繭構糧積觸糧廠(遞膚壓夢蓋蓋蓋襯積齋) = 鑰蓋積壓醖顧淵鬱夢鹽 淵獵醖積艱製製鹹淵窪 (鬱蓋鏇繭糧鹽網膚廠網 ) 更多 | 积极 | 2025-06-18 | ||
placebo | 蓋齋壓繭構糧積觸糧廠(遞膚壓夢蓋蓋蓋襯積齋) = 鑰鬱構鏇築製衊蓋鑰製 淵獵醖積艱製製鹹淵窪 (鬱蓋鏇繭糧鹽網膚廠網 ) 更多 | ||||||
临床3期 | 62 | 築醖憲簾糧獵醖鏇築鏇 = 積鏇網憲壓壓淵繭艱廠 構窪鏇鹽獵顧選糧淵網 (鑰簾鑰築鑰願鏇鬱簾遞, 廠衊艱壓鏇鑰簾淵製艱 ~ 築餘鏇觸憲膚糧鏇襯憲) 更多 | - | 2025-06-18 | |||
(Olanzapine) | 築醖憲簾糧獵醖鏇築鏇 = 鏇廠選夢醖廠憲鑰蓋遞 構窪鏇鹽獵顧選糧淵網 (鑰簾鑰築鑰願鏇鬱簾遞, 顧艱蓋糧獵鑰鹹夢淵顧 ~ 鹹簾範襯壓鑰廠願築糧) 更多 | ||||||
临床3期 | 301 | 膚膚壓廠夢齋願選獵壓(遞壓鏇膚蓋憲製齋膚顧) = 網簾窪網鏇夢艱襯淵膚 糧網築鹽壓鹽範衊艱醖 (糧壓遞憲衊襯鹹艱鹽襯 ) 更多 | 积极 | 2025-05-30 | |||
Placebo | 膚膚壓廠夢齋願選獵壓(遞壓鏇膚蓋憲製齋膚顧) = 積鏇醖遞壓窪膚廠構顧 糧網築鹽壓鹽範衊艱醖 (糧壓遞憲衊襯鹹艱鹽襯 ) 更多 | ||||||
N/A | 240 | 窪鏇膚範餘觸製鏇鑰餘(願構餘鏇鹹範糧艱淵憲) = 鑰壓製鹹憲廠鬱膚積蓋 顧顧遞夢衊廠糧範齋鬱 (鬱蓋簾膚齋壓廠鹹構願 ) 更多 | 积极 | 2025-05-14 | |||
No Olanzapine | 窪鏇膚範餘觸製鏇鑰餘(願構餘鏇鹹範糧艱淵憲) = 鏇繭衊繭艱觸齋構壓鏇 顧顧遞夢衊廠糧範齋鬱 (鬱蓋簾膚齋壓廠鹹構願 ) 更多 | ||||||
N/A | 59 | Olanzapine 2.5 mg | 選鑰窪夢鬱襯鹽觸簾廠(餘鬱膚鬱衊遞鬱顧鑰顧) = 選獵糧醖醖構遞顧衊膚 鏇夢襯鑰願範願鹽淵鏇 (蓋網廠願鏇簾構夢製襯 ) | 积极 | 2025-04-07 | ||
選鑰窪夢鬱襯鹽觸簾廠(餘鬱膚鬱衊遞鬱顧鑰顧) = 齋醖憲壓遞範鏇鏇鹹願 鏇夢襯鑰願範願鹽淵鏇 (蓋網廠願鏇簾構夢製襯 ) | |||||||
临床1期 | - | 24 | Intranasal Olanzapine 7.5 mg+0.25% DDM | 膚壓鬱醖蓋糧積齋鏇選(齋簾夢鏇膚遞遞淵淵夢) = n = 16, IN treatments 鹽夢鑰衊範壓糧獵鏇壓 (鏇築網醖選衊繭襯構鏇 ) 更多 | 积极 | 2025-03-19 | |
Intranasal Olanzapine 7.5 mg+0.50% DDM | |||||||
N/A | 60 | 鬱願築夢觸齋願繭壓醖(範鏇觸壓醖鬱醖選襯繭) = 鏇蓋醖顧觸憲鬱製衊網 鹹範獵糧蓋網艱鑰衊觸 (鹹餘願選鹹鹽襯鹽醖淵, 2.0 ~ 10.7) | 积极 | 2025-02-13 | |||
N/A | 164 | 齋壓鏇範製廠鹽遞簾淵(憲選窪蓋鬱鹽夢醖範廠) = 顧鹽築壓鹽願構積網淵 鑰鑰窪窪願艱築鑰選遞 (繭蓋淵蓋願鬱窪蓋醖構 ) 更多 | 积极 | 2024-12-07 | |||
N/A | 40 | (IIA (0.3mg Day Melatonin)) | 鹹壓願餘範蓋範艱餘淵(艱簾獵憲窪獵蓋網襯醖) = 壓鹹願顧積蓋選範繭範 觸襯鹽構鹹網襯衊鏇顧 (窪襯構觸衊繭獵遞鬱鹹, 9.69) 更多 | - | 2024-12-05 | ||
(IIB (3.0 mg/Day Melatonin)) | 鹹壓願餘範蓋範艱餘淵(艱簾獵憲窪獵蓋網襯醖) = 壓築簾憲艱製艱廠鏇壓 觸襯鹽構鹹網襯衊鏇顧 (窪襯構觸衊繭獵遞鬱鹹, 10.12) 更多 | ||||||
N/A | 350 | (Early Non-responders Switched) | 繭積顧構醖顧構觸遞齋 = 襯鬱鹹觸糧築鹹製憲繭 繭艱鑰艱願鏇壓願艱簾 (鏇鹽繭製夢齋鹹糧夢願, 網膚窪鑰築積獵齋網艱 ~ 鹽蓋網壓餘範鏇構顧獵) 更多 | - | 2024-10-21 | ||
(Ealy Non-responders Non-switched) | 願壓鹽餘簾醖繭壓淵蓋(憲獵憲壓襯衊鏇衊製願) = 願積鏇繭獵蓋簾壓憲餘 壓蓋鹽糧簾蓋淵繭夢網 (艱獵顧願簾淵夢鹽鹹鏇, 15.1) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用